- Home
- OBE vs ACHV Comparison
OBE vs ACHV Comparison
Compare OBE & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBE | ACHV |
|---|---|---|
| Founded | 1979 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.4M | 618.0M |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | OBE | ACHV |
|---|---|---|
| Price | $10.67 | $7.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $14.67 |
| AVG Volume (30 Days) | 824.8K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.44 | $2.55 |
| 52 Week High | $14.59 | $7.34 |
Technical Indicators
Market Signals| Indicator | OBE | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 58.32 | 73.79 |
| Support Level | $9.18 | $4.04 |
| Resistance Level | $10.92 | N/A |
| Average True Range (ATR) | 0.48 | 0.33 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 94.07 | 98.71 |
Price Performance
Historical ComparisonAbout OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Sale of Oil.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.